[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20240246A - Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden - Google Patents

Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden

Info

Publication number
CR20240246A
CR20240246A CR20240246A CR20240246A CR20240246A CR 20240246 A CR20240246 A CR 20240246A CR 20240246 A CR20240246 A CR 20240246A CR 20240246 A CR20240246 A CR 20240246A CR 20240246 A CR20240246 A CR 20240246A
Authority
CR
Costa Rica
Prior art keywords
antibodies
ltbr
agonistic
bispecific
methods
Prior art date
Application number
CR20240246A
Other languages
English (en)
Inventor
Stefan Dengl
Guy Georges
Felix Bormann
Michelle Victoria Brydon
Monika Heidrich
Fanny Mende
Ralf Hosse
Leo Frederik Kunz
Stephane Leclair
Miroslav Nikolov
Pablo Umaña
Desirée Leisibach
Olaf Mundigl
Harald Duerr
Roberta Bianchi
Lydia Jasmin Hanisch
Cornelia Wagner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20240246A publication Critical patent/CR20240246A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a novedosos anticuerpos que se unen al receptor de linfotoxina beta (LTBR) y a moléculas de unión a antígeno biespecíficas que comprenden estos novedosos anticuerpos anti-LTBR y un dominio de unión a antígeno que se une a un antígeno asociado a un tumor, en particular a la proteína de activación de fibroblastos (FAP), a procedimientos de producción de estas moléculas y a procedimientos de uso de las mismas
CR20240246A 2021-12-20 2022-12-09 Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden CR20240246A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21215804 2021-12-20
EP22208828 2022-11-22
PCT/EP2022/086540 WO2023117834A1 (en) 2021-12-20 2022-12-19 Agonistic ltbr antibodies and bispecific antibodies comprising them

Publications (1)

Publication Number Publication Date
CR20240246A true CR20240246A (es) 2024-07-19

Family

ID=84901289

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240246A CR20240246A (es) 2021-12-20 2022-12-09 Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden

Country Status (11)

Country Link
EP (1) EP4453031A1 (es)
KR (1) KR20240122864A (es)
AR (1) AR128031A1 (es)
AU (1) AU2022423749A1 (es)
CO (1) CO2024008179A2 (es)
CR (1) CR20240246A (es)
IL (1) IL313258A (es)
MX (1) MX2024007314A (es)
PE (1) PE20241754A1 (es)
TW (1) TW202340248A (es)
WO (1) WO2023117834A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP5694623B2 (ja) 1999-02-05 2015-04-01 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド 遺伝子操作した動物から得られるヒトポリクローナル抗体
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
WO2001025454A2 (en) 1999-10-04 2001-04-12 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2422155A1 (en) 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
CN1555411A (zh) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ 抗体-依赖性细胞毒性增大的抗体糖基化变体
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP2005532051A (ja) 2002-07-01 2005-10-27 バイオジェン， インコーポレイテッド ヒト化抗リンホトキシンβレセプター抗体
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
AU2004253835B2 (en) 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
KR101220691B1 (ko) 2003-11-05 2013-01-14 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진ｃｄ20 항체
TW200531979A (en) 2003-12-05 2005-10-01 Compound Therapeutics Inc Inhibitors of type 2 vascular endothelial growth factor receptors
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2006047367A2 (en) 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
JP5188969B2 (ja) 2005-08-03 2013-04-24 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド ヒト化免疫グロブリンを発現するトランスジェニック動物におけるｂ細胞アポトーシスの抑制
CN101506235B (zh) 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX350962B (es) 2008-01-07 2017-09-27 Amgen Inc Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
DK2483310T3 (da) * 2009-09-29 2014-09-01 Roche Glycart Ag Bispecifik dødsreceptor-agonistiske antistoffer
RS56702B1 (sr) 2010-08-13 2018-03-30 Roche Glycart Ag Anti-fap antitela i metode primene
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
US10526413B2 (en) * 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
MX2018004157A (es) * 2015-10-07 2019-04-01 F Hoffmann ­La Roche Ag Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
EP3562936B1 (en) 2017-01-02 2024-05-22 F. Hoffmann-La Roche AG B-cell cultivation method
US20220259328A1 (en) * 2019-05-15 2022-08-18 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and fap
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
MX2024007314A (es) 2024-06-26
IL313258A (en) 2024-08-01
KR20240122864A (ko) 2024-08-13
TW202340248A (zh) 2023-10-16
PE20241754A1 (es) 2024-08-28
EP4453031A1 (en) 2024-10-30
AU2022423749A1 (en) 2024-06-13
WO2023117834A1 (en) 2023-06-29
AR128031A1 (es) 2024-03-20
CO2024008179A2 (es) 2024-07-29

Similar Documents

Publication Publication Date Title
WO2019074973A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CR20220479A (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CR20220019A (es) Anticuerpos que se fijan a gprc5d
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
MX2022006230A (es) Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
AU2020224154A8 (en) Multifunctional molecules that bind to calreticulin and uses thereof
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2023003522A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
MX2024007314A (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden.
MX2023009022A (es) Anticuerpos multiespecificos con especificidad para ror1 y cd3.
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2022007353A (es) Anticuerpos novedosos ddr1 y sus usos.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
MX2023010333A (es) Tratamiento conjunto de inmunoconjugados de variante il-2 que actuan sobre pd-1-y moleculas de union a fap/4-1bb.
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
WO2022157773A3 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
CR20230245A (es) Moléculas de unión a gucy2c y sus usos
AR120430A1 (es) Células car-t dirigidas a epha3 para el tratamiento de tumores